In conclusion, the present study demonstrates that dauricine significantly enhances the antitumor effects of sorafenib in NSCLC known as non-small cell lung cancer by modulating key cancer signaling pathways, particularly those mediated by HIF-1α. Here, HIF1A is linked to non-small cell lung carcinoma.